Cargando…

Challenges and opportunities for the future of monoclonal antibody development: Improving safety assessment and reducing animal use

The market for biotherapeutic monoclonal antibodies (mAbs) is large and is growing rapidly. However, attrition poses a significant challenge for the development of mAbs, and for biopharmaceuticals in general, with large associated costs in resource and animal use. Termination of candidate mAbs may o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sewell, Fiona, Chapman, Kathryn, Couch, Jessica, Dempster, Maggie, Heidel, Shawn, Loberg, Lise, Maier, Curtis, Maclachlan, Timothy K., Todd, Marque, van der Laan, Jan Willem
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2017
Materias:	Meeting Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5524158/ https://www.ncbi.nlm.nih.gov/pubmed/28475417 http://dx.doi.org/10.1080/19420862.2017.1324376

Ejemplares similares

Testing Chemical Safety: What Is Needed to Ensure the Widespread Application of Non-animal Approaches?
por: Burden, Natalie, et al.
Publicado: (2015)

Canola/Rapeseed Protein: Future Opportunities and Directions—Workshop Proceedings of IRC 2015
por: Campbell, Lisa, et al.
Publicado: (2016)

Process development of ATROSAB, an anti TNFR1 Monoclonal Antibody: in three steps from research to GMP
por: Landauer, Karlheinz, et al.
Publicado: (2011)

The future of fungi: threats and opportunities
por: Case, Nicola T, et al.
Publicado: (2022)

Opportunities to Apply the 3Rs in Safety Assessment Programs
por: Sewell, Fiona, et al.
Publicado: (2016)

Single use bioreactors for the clinical production of monoclonal antibodies – a study to analyze the performance of a CHO cell line and the quality of the produced monoclonal antibody
por: Diekmann, Sonja, et al.
Publicado: (2011)

Human papillomavirus vaccination in adults: impact, opportunities and challenges – a meeting report
por: Waheed, Dur-e-Nayab, et al.
Publicado: (2021)

Proteins function for anti-senescence and monoclonal proliferation of ATL cells
por: Pornkuna, Ratiorn, et al.
Publicado: (2011)

Health impact of probiotics - vision and opportunities
por: Hajela, Neerja, et al.
Publicado: (2012)

Geriatric day surgery: challenge or opportunity?
por: Grifasi, Carlo, et al.
Publicado: (2013)

Platform process for production of monoclonal antibodies for research purposes – improvement option
por: Petersen, Joern Meidahl, et al.
Publicado: (2011)

Knowledge translation opportunities in allergic disease and asthma
por: Royce, Diana
Publicado: (2010)

Immunoglobulin abnormalities and monoclonal gammopathy of undetermined significance in uninfected and HIV-infected men
por: Breen, Elizabeth Crabb, et al.
Publicado: (2010)

Opportunities of predictive medicine at the treatment of diabetes mellitus complications
por: Sautin, Maxim, et al.
Publicado: (2014)

Medium and feed optimization for fed-batch production of a monoclonal antibody in CHO cells
por: Kochanowski, Nadine, et al.
Publicado: (2011)

Characterization of binding interactions in solution between β-2-glycoprotein I and monoclonal antibodies
por: Heegaard, NHH, et al.
Publicado: (2002)

Anti-Ige monoclonal antibody therapy for the treatment of chronic rhinosinusitis: a systematic review
por: Hong, Chris J, et al.
Publicado: (2014)

Advances in the applications of monoclonal antibodies in clinical oncology 25/27 may 1988. Abstracts of the proceedings
Publicado: (1989)

Disulphide bond reduction of a therapeutic monoclonal antibody during cell culture manufacturing operations
por: Mullan, Brian, et al.
Publicado: (2011)

Preliminary evaluation of microcarrier culture for growth and monoclonal antibody production of CHO-K1 cells
por: Rodrigues, M Elisa, et al.
Publicado: (2011)

Immunodiagnosis and therapeutic immunosuppression in rheumatoid arthritis with ior t1 (anti-CD6) monoclonal antibody
por: Montero, E, et al.
Publicado: (2002)

Integration sites of the HTLV-1 provirus in host human genome in the IDH patients with monoclonal integration
por: Argolo, Juliana M, et al.
Publicado: (2011)

Cytokine signalling: new insights and new opportunities for therapeutic intervention?
por: O'Shea, JJ
Publicado: (2001)

Leveraging existing opportunities for improved Orphan Drug approval in the EU
por: Edfjäll, Catarina
Publicado: (2012)

Challenges, Progress, and Opportunities: Proceedings of the Filovirus Medical Countermeasures Workshop
por: Hirschberg, Rona, et al.
Publicado: (2014)

The opportunity and imperative for point-of-care diagnostics in systemic lupus erythematosus
por: Fritzler, Marvin J
Publicado: (2014)

Pricing the national health insurance scheme in Qatar – opportunities and challenges
por: Goldner, Finn, et al.
Publicado: (2015)

Challenges and opportunities of software automation discussed at the Yanqi-Lake Meeting
por: Jiang, He
Publicado: (2019)

Animal population ecology
por: Dempster, J. P. 1930- (Jack P.)
Publicado: (1975)

Off-target binding of an anti-amyloid beta monoclonal antibody to platelet factor 4 causes acute and chronic toxicity in cynomolgus monkeys
por: Loberg, Lise I., et al.
Publicado: (2021)

Allergic diseases of the skin and drug allergies – 2017. Rapid desensitization for delayed reactions to chemotherapy and monoclonal antibodies
por: Vega Castro, Maria Aranzazu, et al.
Publicado: (2013)

Biotherapeutics: Challenges and Opportunities for Predictive Toxicology of Monoclonal Antibodies
por: Johnson, Dale E.
Publicado: (2018)

Artemisinin-Resistant Malaria: Research Challenges, Opportunities, and Public Health Implications
por: Fairhurst, Rick M., et al.
Publicado: (2012)

Engaging basic scientists in translational research: identifying opportunities, overcoming obstacles
por: Hobin, Jennifer A, et al.
Publicado: (2012)

The human proteome – a scientific opportunity for transforming diagnostics, therapeutics, and healthcare
por: Vidal, Marc, et al.
Publicado: (2012)

Planning for pre-exposure prophylaxis to prevent HIV transmission: challenges and opportunities
por: Kim, Susan C, et al.
Publicado: (2010)

Ovarian disorders in domestic animals.
por: MacLachlan, N J
Publicado: (1987)

Use of Micro Bioreactor systems to streamline cell line evaluation and upstream process development for monoclonal antibody production
por: Warr, Steve R C, et al.
Publicado: (2011)

EHMTI-0315. AMG 334, the first potent and selective human monoclonal antibody antagonist against the CGRP receptor
por: Xu, C, et al.
Publicado: (2014)

Anti-Ige monoclonal antibody therapy for the treatment of patients with chronic rhinosinusitis: a multi-disciplinary practice review
por: Kilty, Shaun J, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_rcatup5vu5mmsjkka31jjbcfqu